DDInter675 DDInter826
Esmolol, commonly marketed under the trade name Brevibloc, is a cardioselective beta-1 receptor blocker. It has a rapid onset but short duration of action without causing significant intrinsic sympathomimetic or membrane stabilizing activities at recommended therapeutic doses. It works by blocking beta-adrenergic receptors in the heart, which leads to decreased force and rate of heart contractions. Esmolol prevents the action of two naturally occurring substances: epinephrine and norepinephrine. The FDA withdrew its approval for the use of all parenteral dosage form drug products containing esmolol hydrochloride that supply 250 milligrams/milliliter of concentrated esmolol per 10-milliliter ampule. Other esmolol formulations are still available for use.
Glipizide is an oral hypoglycemic agent in the second-generation sulfonylurea drug class that is used to control blood sugar levels in patients with type 2 diabetes mellitus. It was first introduced in 1984 and is available in various countries including Canada and the U.S. According to the 2018 Clinical Practice Guidelines by Diabetes Canada, sulfonylurea drugs are considered a second-line glucose-lowering therapy following metformin. Because sulfonylureas require functional pancreatic beta cells for their therapeutic effectiveness, sulfonylureas are more commonly used for early-stage type 2 diabetes when there is no progressed pancreatic failure. Compared to the first-generation sulfonylureas, such as [tolbutamide] and [chlorpropamide], second-generation sulfonylureas contain a more non-polar side chain in their chemical structure, which enhances their hypoglycemic potency. Compared to other members of the sulfonylurea drug group, glipizide displays rapid absorption and onset of action with the shortest half-life and duration of action, reducing the risk for long-lasting hypoglycemia that is often observed with blood glucose-lowering agents. Glipizide was first approved by the FDA in 1994 and is available in extended-release tablets under the brand name Glucotrol®, as well as in combination with metformin under the brand name Metaglip®.
Esmolol {u} (Compound) downregulates {v} (Gene) JMJD6
JMJD6 {u} (Gene) is downregulated by {v} (Compound) Glipizide
Esmolol {u} (Compound) causes {v} (Side Effect) Abnormal vision
Abnormal vision {u} (Side Effect) is caused by {v} (Compound) Glipizide
Esmolol {u} (Compound) resembles {v} (Compound) Metoprolol
Metoprolol {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Glipizide
Esmolol {u} (Compound) resembles {v} (Compound) Ibuprofen
Ibuprofen {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Glipizide
Esmolol {u} (Compound) resembles {v} (Compound) Acebutolol
Acebutolol {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Glipizide
Esmolol {u} (Compound) downregulates {v} (Gene) JMJD6
JMJD6 {u} (Gene) is regulated by {v} (Gene) TLR4
TLR4 {u} (Gene) is upregulated by {v} (Compound) Glipizide
Esmolol {u} (Compound) causes {v} (Side Effect) Abnormal vision
Abnormal vision {u} (Side Effect) is caused by {v} (Compound) Gliclazide
Gliclazide {u} (Compound) resembles {v} (Compound) Glipizide
Esmolol {u} (Compound) causes {v} (Side Effect) Erythema
Erythema {u} (Side Effect) is caused by {v} (Compound) Glyburide
Glyburide {u} (Compound) resembles {v} (Compound) Glipizide
Esmolol {u} (Compound) causes {v} (Side Effect) Dysuria
Dysuria {u} (Side Effect) is caused by {v} (Compound) Esomeprazole
Esomeprazole {u} may cause a minor interaction that can limit clinical effects when taken with {v} Glipizide
Esmolol {u} (Compound) causes {v} (Side Effect) Syncope
Syncope {u} (Side Effect) is caused by {v} (Compound) Dexamethasone
Dexamethasone {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Glipizide
Esmolol (Compound) downregulates JMJD6 (Gene) and JMJD6 (Gene) is downregulated by Glipizide (Compound)
Esmolol (Compound) causes Abnormal vision (Side Effect) and Abnormal vision (Side Effect) is caused by Glipizide (Compound)
Esmolol (Compound) resembles Metoprolol (Compound) and Metoprolol may cause a moderate interaction that could exacerbate diseases when taken with Glipizide
Esmolol (Compound) resembles Ibuprofen (Compound) and Ibuprofen may cause a moderate interaction that could exacerbate diseases when taken with Glipizide
Esmolol (Compound) resembles Acebutolol (Compound) and Acebutolol may cause a moderate interaction that could exacerbate diseases when taken with Glipizide
Esmolol (Compound) downregulates JMJD6 (Gene) and JMJD6 (Gene) is regulated by TLR4 (Gene) and TLR4 (Gene) is upregulated by Glipizide (Compound)
Esmolol (Compound) causes Abnormal vision (Side Effect) and Abnormal vision (Side Effect) is caused by Gliclazide (Compound) and Gliclazide (Compound) resembles Glipizide (Compound)
Esmolol (Compound) causes Erythema (Side Effect) and Erythema (Side Effect) is caused by Glyburide (Compound) and Glyburide (Compound) resembles Glipizide (Compound)
Esmolol (Compound) causes Dysuria (Side Effect) and Dysuria (Side Effect) is caused by Esomeprazole (Compound) and Esomeprazole may cause a minor interaction that can limit clinical effects when taken with Glipizide
Esmolol (Compound) causes Syncope (Side Effect) and Syncope (Side Effect) is caused by Dexamethasone (Compound) and Dexamethasone may cause a moderate interaction that could exacerbate diseases when taken with Glipizide